Assyro AI

FDA Orange Book · active-ingredient family

Vasopressin

Vasopressin is approved as 4 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

4

Brand (NDA)

10

Generics (ANDA)

16

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution

ProductApplicantApplicationTEApproved
VASOPRESSIN IN SODIUM CHLORIDE 0.9%RLD×3LONG GROVE PHARMSNDA 217766Jul 11, 2024
VASOPRESSIN IN SODIUM CHLORIDE 0.9%RLD×2BAXTER HLTHCARE CORPNDA 217569Sep 29, 2023
VASOPRESSINRLD×2AM REGENTNDA 212593Aug 03, 2020
VASOSTRICTRLD×6PH HEALTHNDA 204485APApr 17, 2014

Generic (ANDA) products (10)

ProductApplicantApplicationTEApproved
VASOPRESSINSANDOZANDA 212068APMay 06, 2026
VASOPRESSINSANDOZANDA 212069APMay 06, 2026
VASOPRESSIN×2DR REDDYSANDA 213988APMay 08, 2024
VASOPRESSIN×2GLANDANDA 216963APFeb 09, 2024
VASOPRESSINCIPLAANDA 217987APDec 06, 2023
VASOPRESSINFRESENIUS KABI USAANDA 213206APMay 26, 2023
VASOPRESSINEUGIA PHARMAANDA 214314APAug 15, 2022
VASOPRESSINAMNEALANDA 212944APAug 05, 2022
VASOPRESSINAMPHASTAR PHARMS INCANDA 211857APJul 18, 2022
VASOPRESSINEAGLE PHARMSANDA 211538Dec 15, 2021

Listed patents (16)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9744209Jan 30, 2035in 8 yr 9 mo
U-1857
9375478Jan 30, 2035in 8 yr 9 mo
U-1857
9744239Jan 30, 2035in 8 yr 9 mo
U-1857
9687526Jan 30, 2035in 8 yr 9 mo
U-1857
9750785Jan 30, 2035in 8 yr 9 mo
Product
10010575Jan 30, 2035in 8 yr 9 mo
U-1857
9981006Jan 30, 2035in 8 yr 9 mo
U-1857
9974827Jan 30, 2035in 8 yr 9 mo
U-1857
9968649Jan 30, 2035in 8 yr 9 mo
U-1857
9962422Jan 30, 2035in 8 yr 9 mo
U-1857
9925234Jan 30, 2035in 8 yr 9 mo
U-1857
9925233Jan 30, 2035in 8 yr 9 mo
U-1857
12186362Jan 30, 2035in 8 yr 9 mo
Product
9919026Jan 30, 2035in 8 yr 9 mo
Product
9937223Jan 30, 2035in 8 yr 9 mo
U-1857
12447190Sep 27, 2044in 18 yr 7 mo
Product

Vasopressin — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.